Kairos Pharma Announces New Department of Defense Funding for Research of ENV205
Kairos Pharma (NYSE American: KAPA) announces that its academic partner Cedars-Sinai Medical Center has received $600,000 in funding from the Department of Defense Lung Cancer Research Program to advance the development of ENV205.
ENV205 is a first-in-class therapy designed to reverse chemotherapy drug resistance, counteract muscle loss, improve strength, and enhance the effectiveness of existing cancer treatments. The drug targets key pathways driving cachexia, a severe muscle-wasting condition affecting over half of cancer patients, characterized by involuntary weight loss, muscle atrophy, and systemic inflammation.
The funding will accelerate research efforts through the company's ongoing partnership with Cedars-Sinai Medical Center, aiming to advance the therapy toward clinical trials.
Kairos Pharma (NYSE American: KAPA) annuncia che il suo partner accademico Cedars-Sinai Medical Center ha ricevuto 600.000 dollari di finanziamento dal Programma di Ricerca sul Cancro ai Polmoni del Dipartimento della Difesa per promuovere lo sviluppo di ENV205.
ENV205 è una terapia innovativa progettata per invertire la resistenza ai farmaci chemioterapici, contrastare la perdita di massa muscolare, migliorare la forza e aumentare l'efficacia dei trattamenti oncologici esistenti. Il farmaco colpisce i percorsi chiave che guidano la cachessia, una grave condizione di perdita muscolare che colpisce oltre la metà dei pazienti oncologici, caratterizzata da perdita di peso involontaria, atrofia muscolare e infiammazione sistemica.
Il finanziamento accelererà gli sforzi di ricerca attraverso la continua collaborazione della società con il Cedars-Sinai Medical Center, con l'obiettivo di portare la terapia verso sperimentazioni cliniche.
Kairos Pharma (NYSE American: KAPA) anuncia que su socio académico Cedars-Sinai Medical Center ha recibido $600,000 en financiamiento del Programa de Investigación del Cáncer de Pulmón del Departamento de Defensa para avanzar en el desarrollo de ENV205.
ENV205 es una terapia de primera clase diseñada para revertir la resistencia a los fármacos de quimioterapia, contrarrestar la pérdida de masa muscular, mejorar la fuerza y aumentar la eficacia de los tratamientos oncológicos existentes. El fármaco se dirige a vías clave que impulsan la caquexia, una grave condición de pérdida muscular que afecta a más de la mitad de los pacientes con cáncer, caracterizada por pérdida de peso involuntaria, atrofia muscular e inflamación sistémica.
El financiamiento acelerará los esfuerzos de investigación a través de la colaboración continua de la empresa con el Cedars-Sinai Medical Center, con el objetivo de avanzar en la terapia hacia ensayos clínicos.
카이로스 제약 (NYSE American: KAPA)는 학술 파트너인 시더스-사이 나이 메디컬 센터가 방위부 폐암 연구 프로그램으로부터 600,000달러의 자금을 지원받았다고 발표했습니다. 이는 ENV205의 개발을 추진하기 위한 것입니다.
ENV205는 화학요법 약물 저항성을 역전시키고, 근육 손실을 방지하며, 힘을 개선하고, 기존 암 치료의 효과를 높이기 위해 설계된 최초의 치료법입니다. 이 약물은 체중 감소, 근육 위축 및 전신 염증으로 특징지어지는 심각한 근육 소모 상태인 카케시아를 유발하는 주요 경로를 타겟으로 합니다. 이 상태는 암 환자의 절반 이상에게 영향을 미칩니다.
이번 자금 지원은 회사가 시더스-사이나이 메디컬 센터와 지속적인 파트너십을 통해 연구 노력을 가속화하여 임상 시험을 향한 치료 발전을 목표로 합니다.
Kairos Pharma (NYSE American: KAPA) annonce que son partenaire académique Cedars-Sinai Medical Center a reçu 600 000 $ de financement du Programme de recherche sur le cancer du poumon du Département de la Défense pour faire progresser le développement de ENV205.
ENV205 est une thérapie de première classe conçue pour inverser la résistance aux médicaments de chimiothérapie, contrer la perte musculaire, améliorer la force et renforcer l'efficacité des traitements contre le cancer existants. Le médicament cible des voies clés à l'origine de la cachexie, une grave condition de perte musculaire touchant plus de la moitié des patients atteints de cancer, caractérisée par une perte de poids involontaire, une atrophie musculaire et une inflammation systémique.
Le financement accélérera les efforts de recherche grâce au partenariat continu de l'entreprise avec le Cedars-Sinai Medical Center, visant à faire avancer la thérapie vers des essais cliniques.
Kairos Pharma (NYSE American: KAPA) gibt bekannt, dass sein akademischer Partner Cedars-Sinai Medical Center 600.000 US-Dollar an Fördergeldern vom Lung Cancer Research Program des Verteidigungsministeriums erhalten hat, um die Entwicklung von ENV205 voranzutreiben.
ENV205 ist eine neuartige Therapie, die entwickelt wurde, um die Resistenz gegen Chemotherapien umzukehren, Muskelverlust entgegenzuwirken, die Kraft zu verbessern und die Wirksamkeit bestehender Krebsbehandlungen zu erhöhen. Das Medikament zielt auf Schlüsselwege ab, die die Kachexie vorantreiben, einen schweren Zustand des Muskelabbaus, der mehr als die Hälfte der Krebspatienten betrifft und durch unbeabsichtigten Gewichtsverlust, Muskelatrophie und systemische Entzündung gekennzeichnet ist.
Die Finanzierung wird die Forschungsanstrengungen durch die laufende Partnerschaft des Unternehmens mit dem Cedars-Sinai Medical Center beschleunigen, mit dem Ziel, die Therapie in Richtung klinische Studien voranzubringen.
- Secured $600,000 in non-dilutive funding from Department of Defense
- Development of first-in-class therapy targeting both chemotherapy resistance and cachexia
- Addresses large market opportunity with over 50% of cancer patients affected by cachexia
- Drug still in early research phase, not yet in clinical trials
- Funding amount relatively modest for drug development
Insights
The
ENV205's unique dual-targeting approach addressing both chemotherapy resistance and cachexia positions it distinctively in the oncology market. Cachexia affects
The partnership with Cedars-Sinai Medical Center provides important advantages: access to world-class research facilities, potential patient recruitment channels for future clinical trials, and institutional credibility that could facilitate additional grant funding or strategic partnerships. The Department of Defense's involvement also suggests potential future military applications or additional funding opportunities through federal channels.
While the funding amount is modest relative to typical drug development costs, it enables specific research objectives that could generate valuable data for future development phases. The company's strategy of leveraging non-dilutive funding and academic partnerships demonstrates efficient capital allocation, particularly important given current market conditions and the competitive nature of biotech funding.
This funding will accelerate the Company’s research efforts to develop ENV205, a first-in-class therapy designed to reverse chemotherapy drug resistance, counteract muscle loss, improve strength, and enhance the effectiveness of existing cancer treatments. By targeting key pathways that drive cachexia, Kairos seeks to develop ENV205 to provide a much-needed solution to help patients maintain their health and resilience throughout cancer therapy. The Company has long been partnering with Cedars-Sinai in its research and development of ENV205.
Neil Bhowmick, Kairos Pharma’s Chief Scientific Officer, stated, “We are grateful to our supporters and collaborators who share our vision of improving outcomes for cancer patients worldwide. We look forward to collaborating with the Department of Defense to advance this promising new therapy toward clinical trials.”
Dr. John Yu, Kairos Pharma’s Chief Executive Officer, added, “Developing our therapeutics through non-dilutive federal funding has been a hallmark of Kairos’s success in drug development and underscores the excellence of our scientific team.”
Cachexia is a severe muscle-wasting condition that affects over half of cancer patients and significantly impacts quality of life, treatment tolerance, and survival. It is a complex metabolic syndrome characterized by involuntary weight loss, muscle atrophy, and systemic inflammation, which currently lacks effective treatment options.
About Kairos Pharma Ltd.
Based in
CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s prospectus filed with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218885970/en/
CORE IR
Louie Toma
investors@kairospharma.com
Source: Kairos Pharma, Ltd
FAQ
What is the purpose of the $600,000 Department of Defense grant received by KAPA's partner?
What medical conditions does KAPA's ENV205 drug target?
How many cancer patients could potentially benefit from KAPA's ENV205 treatment?
What stage of development is KAPA's ENV205 drug currently in?
What is the partnership structure between KAPA and Cedars-Sinai for ENV205 development?
